Aurobindo Pharma Statistics

Total Valuation

Aurobindo Pharma has a market cap or net worth of INR 721.18 billion. The enterprise value is 736.84 billion.

Market Cap	721.18B
Enterprise Value	736.84B

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.49%
Shares Change (QoQ)	-0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	272.84M

Valuation Ratios

The trailing PE ratio is 20.14.

PE Ratio	20.14
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.68
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.43, with an EV/FCF ratio of -148.80.

EV / Earnings	20.57
EV / Sales	2.43
EV / EBITDA	11.43
EV / EBIT	14.84
EV / FCF	-148.80

Financial Position

The company has a current ratio of 1.83, with a Debt / Equity ratio of 0.27.

Current Ratio	1.83
Quick Ratio	0.85
Debt / Equity	0.27
Debt / EBITDA	1.30
Debt / FCF	-17.02
Interest Coverage	13.57

Financial Efficiency

Return on equity (ROE) is 12.13% and return on invested capital (ROIC) is 8.39%.

Return on Equity (ROE)	12.13%
Return on Assets (ROA)	6.77%
Return on Capital (ROIC)	8.39%
Revenue Per Employee	11.65M
Profits Per Employee	1.38M
Employee Count	26,015
Asset Turnover	0.66
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.14% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.14%
50-Day Moving Average	1,325.18
200-Day Moving Average	1,297.00
Relative Strength Index (RSI)	44.43
Average Volume (20 Days)	20,068

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aurobindo Pharma had revenue of INR 302.95 billion and earned 35.82 billion in profits. Earnings per share was 61.31.

Revenue	302.95B
Gross Profit	174.18B
Operating Income	49.80B
Pretax Income	50.24B
Net Income	35.82B
EBITDA	63.95B
EBIT	49.80B
Earnings Per Share (EPS)	61.31

Full Income Statement

Balance Sheet

The company has 68.68 billion in cash and 84.27 billion in debt, giving a net cash position of -15.59 billion.

Cash & Cash Equivalents	68.68B
Total Debt	84.27B
Net Cash	-15.59B
Net Cash Per Share	n/a
Equity (Book Value)	308.85B
Book Value Per Share	528.88
Working Capital	118.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.87 billion and capital expenditures -20.82 billion, giving a free cash flow of -4.95 billion.

Operating Cash Flow	15.87B
Capital Expenditures	-20.82B
Free Cash Flow	-4.95B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 57.49%, with operating and profit margins of 16.44% and 11.82%.

Gross Margin	57.49%
Operating Margin	16.44%
Pretax Margin	16.58%
Profit Margin	11.82%
EBITDA Margin	21.11%
EBIT Margin	16.44%
FCF Margin	n/a

Dividends & Yields

Aurobindo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-40.00%
Years of Dividend Growth	n/a
Payout Ratio	7.38%
Buyback Yield	0.49%
Shareholder Yield	0.49%
Earnings Yield	4.94%
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on July 20, 2015. It was a forward split with a ratio of 2.

Last Split Date	Jul 20, 2015
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a